Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. May 15, 2023; 15(5): 859-877
Published online May 15, 2023. doi: 10.4251/wjgo.v15.i5.859
Published online May 15, 2023. doi: 10.4251/wjgo.v15.i5.859
Real-world 10-year retrospective study of the guidelines for diagnosis and treatment of primary liver cancer in China
Yun-Wei Yan, Qing-Feng Tian, Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan Province, China
Xin-Kui Liu, Department of Medical Records Management, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450001, Henan Province, China
Shun-Xiang Zhang, Department of Epidemiology and Health Statistics and Henan Key Laboratory for Tumour Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan Province, China
Author contributions: Yan YW, Zhang SX and Tian QF designed the study; Yan YW and Liu XK performed the data collection and conducted the data analysis; Yan YW wrote the manuscript; Zhang SX and Tian QF revised the manuscript; all authors approved the final version of the manuscript.
Supported by The Major Project of Science and Technology in Henan Province , No. 161100311400 .
Institutional review board statement: The study was approved by the Institutional review board of Zhengzhou University, No. ZZUIRB2022-151.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qing-Feng Tian, PhD, Professor, Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, No. 100 Kexue Avenue, Zhengzhou 450001, Henan Province, China. tianqf@zzu.edu.cn
Received: December 5, 2022
Peer-review started: December 5, 2022
First decision: February 21, 2023
Revised: March 6, 2023
Accepted: April 4, 2023
Article in press: April 4, 2023
Published online: May 15, 2023
Peer-review started: December 5, 2022
First decision: February 21, 2023
Revised: March 6, 2023
Accepted: April 4, 2023
Article in press: April 4, 2023
Published online: May 15, 2023
Core Tip
Core Tip: This retrospective study evaluated the current situation and problems associated with the Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China. The findings revealed that 70% of hepatocellular carcinoma (HCC) treatments at the First Affiliated Hospital of Zhengzhou University were performed according to the guidelines. Patients who underwent liver resection in accordance with the guidelines had a significant survival advantage. Furthermore, screening for HCC high-risk groups according to the guidelines can achieve early diagnosis and treatment; however, real-world compliance is poor.